Neurologists Report Frustration with Efficacy and Logistical Issues Around Eisai/Biogen’s Leqembi, According to Spherix Global Insights Neurologist Survey
Spherix Global Insight’s January update from their Launch Dynamix™: Leqembi in Alzheimer’s Disease (US) service sheds light on neurologists’ early reactions to Leqembi.
- Spherix Global Insight’s January update from their Launch Dynamix™: Leqembi in Alzheimer’s Disease (US) service sheds light on neurologists’ early reactions to Leqembi.
- Analysis from 75 high-prescribing U.S. neurologists reveals the potential reasons behind the even slower-than-expected adoption of Leqembi for treatment of early AD.
- Six months after the full commercial launch of Leqembi, few surveyed neurologists consider Leqembi to be a significant medical advance over other historical AD treatments.
- For all these reasons, Spherix will continue tracking neurologists’ attitudes and use of DMTs in AD well into the future.